Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US6047491013
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00MH7T2M7
TKOMF
Mirum Pharmaceuticals Inc
GICS: Health Care · SECTOR: Financial Services · SUB-SECTOR: Insurance—Property & Casualty · THEMEFOLIO: $HLTH
NAME
Mirum Pharmaceuticals Inc
ISIN
US6047491013
TICKER
TKOMF
MIC
XOTC
REUTERS
TKOMF.PK
BLOOMBERG
TKOMF US
So., 03.05.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, May 4, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC). Conference Call Details: US/Toll-Free: + 1 833 461...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will report first quarter 2026 financial results on May 6, 2026. Mirum will also host a conference call to discuss the first quarter 2026 financial results and recent corporate progress. Conference call details: Wednesday, May 6, 2026 4:30 p.m. ET...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 27.04.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an investigational monoclonal antibody designed to bind hepatitis B surface antigen (HBsAg), for the treatment of chronic hepatitis delta virus (HDV). The Pha...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 13.04.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on April 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 13,700 shares of common stock and 18,200 restricted stock units (“RSUs”) to 12 new employees und...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 16.03.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in EXPAND, a Phase 3 randomized, double-blind, placebo-controlled study evaluating LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with rare cholestatic liver diseases, including...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on March 11, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 5,400 shares of common stock and 6,800 restricted stock units (“RSUs”) to five new employees und...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Do., 05.03.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4 study, both evaluating brelovitug for the treatment of chronic hepatitis delta virus (HDV). Achievement of these milestones confirms the expected timing...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mi., 25.02.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today reported financial results for the fourth quarter and year-end 2025 and provided a business update. “2025 was a year of meaningful progress and execution for Mirum, setting the stage for a pivotal 2026,” said Chris Peetz, Chief Executive Officer of Mirum. “With the...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 23.02.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences: TD Cowen’s 46th Annual Health Care Conference: Monday, March 2, 2026 Company fireside chat starting at 1:10 p.m. ET The Citizens Life Sciences Conference: Tuesday, March 10...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mi., 18.02.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will report fourth quarter and year-end 2025 financial results on February 25, 2026. Mirum will also host a conference call to discuss the fourth quarter and year-end 2025 financial results and recent corporate progress. Conference call details: Wednesday, February 25, 2026 4:30...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 11.02.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on February 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 163,040 shares of common stock, 219,090 restricted stock units (“RSUs”), and 48,880 performance stock units (“PSUs”) to 37 new...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Do., 05.02.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized the tablet formulation of LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). LIVMARLI had previously been authorized in Canada as an oral solution for the treatmen...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Do., 05.02.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized LIVMARLI® (maralixibat) oral solution and tablet formulation for the treatment of cholestatic pruritus in patients aged 12 months or older with progressive familial intrahepatic cholestasis (PFIC). PFIC is a rare, inherit...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 26.01.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a leading rare disease company, today announced the successful completion of its acquisition of Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. With the completion of the acquisition, Mirum adds worldwide rights to brelovitug, a late-stage, fully human...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 12.01.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on January 9, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 4,900 shares of common stock and 6,500 restricted stock units (“RSUs”) to five new employees under Mirum’s 2020 Inducement Plan....
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 12.01.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today provided its preliminary and unaudited estimates for full-year 2025 net product sales, year-end cash balance, corporate updates and full-year 2026 outlook. “2025 was an excellent year for Mirum, reflecting the strength and scalability of our purpose-built rare dise...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mi., 07.01.2026       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 11:15 a.m. PT. The presentation and question and answer session will be webcast live and can be accessed by visiting the Inves...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Fr., 19.12.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it has entered into a subscription agreement with entities associated with TCGX, an institutional investor, for a private placement of 1,000,000 shares of its common stock (the “Common Stock”). The Common Stock issued to the private placement investors...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Do., 11.12.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 15,820 shares of common stock and 7,840 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement P...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 08.12.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. The transaction would add worldwide rights to brelovitug, a late-stage, fully human monoclonal antibody with B...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 01.12.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that the first participant has been enrolled in the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS). Caused by a mutation of the FMR1 gene, FXS is the most common inherited form of intellectual disability and autism spectrum di...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Di., 25.11.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: 8th Annual Evercore HealthCONx Conference on T...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Di., 11.11.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on November 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 53,500 shares of common stock and 27,950 restricted stock units (“RSUs”) to 11 new employees under Mirum’s 2020 Inducement Pla...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Fr., 07.11.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that multiple presentations featuring data from its LIVMARLI (maralixibat) and volixibat clinical programs will be shared during the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting®, taking place November 7-11, 2025, in Washi...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2025 and provided a business update. “Mirum is well positioned heading into 2026 with strong commercial momentum and multiple upcoming catalysts,” said Chris Peetz, Chief Executive Officer of Mirum. "Our third quarter results once again underscore th...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 03.11.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: 2025 Stifel Healthcare Conference Company p...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Di., 28.10.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will report third quarter 2025 financial results on November 4, 2025. Mirum will also host a conference call to discuss the third quarter 2025 financial results and recent corporate progress. Conference call details: Tuesday November 4th, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-In:...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Sa., 11.10.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on October 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 45,800 shares of common stock and 22,850 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement P...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Do., 11.09.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on September 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 10,820 shares of common stock and 5,390 restricted stock units (“RSUs”) to four new employees under Mirum’s 2020 Inducement P...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 08.09.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the completion of enrollment in the Phase 2b VISTAS study of volixibat, an investigational oral IBAT inhibitor, for the treatment of cholestatic pruritus in patients with primary sclerosing cholangitis (PSC). The trial previously met its pre-specified efficacy and safety thresholds at the...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mi., 27.08.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: Citi Biopharma Back-to-School Summit on Wedne...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mi., 30.07.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will report second quarter 2025 financial results on August 6, 2025. Mirum will also host a conference call to discuss the second quarter 2025 financial results and recent corporate progress. Conference call details: Wednesday, August 6th, 2025 4:30 p.m. ET / 1:30 p.m. PT D...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Fr., 11.07.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 14,460 shares of common stock and 7,220 restricted stock units (“RSUs”) to two new employees under Mirum’s 2020 Inducement Plan. T...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mi., 11.06.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 115,620 shares of common stock and 57,740 restricted stock units (“RSUs”) to 10 new employees under Mirum’s 2020 Inducement Plan....
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 19.05.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., wh...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mi., 14.05.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: 3rd Annual H.C. Wainwright BioConnect Investor...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Sa., 10.05.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 9, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 53,230 shares of common stock and 26,585 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement Plan....
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Fr., 09.05.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today presented new data from its Phase 2b VANTAGE study at the European Association for the Study of the Liver (EASL) meeting in Amsterdam, the Netherlands. The VANTAGE study is evaluating volixibat in patients with cholestatic pruritus caused by primary biliary cholangitis (PBC). “The extended VANTAGE...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the first quarter 2025 and provided a business update. “It’s been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline,” said Chris Peetz, chief executive officer of Mirum. “We’re pleased with the FDA’s approval of LIM...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mi., 30.04.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also host a conference call to discuss the first quarter 2025 financial results and recent corporate progress. Conference call details: Wednesday, May 7, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 28.04.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present data at three upcoming medical congresses. Digestive Disease Week (DDW) will be held in San Diego, May 3-6, 2025. The European Association for the Study of the Liver (EASL) will take place May 7-10 in Amsterdam, the Netherlands. The 57th European Society for Paediatric...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 14.04.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC). “The approval of LIVMARLI in tabl...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Fr., 11.04.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 39,740 shares of common stock and 19,830 restricted stock units (“RSUs”) to seven new employees under Mirum’s 2020 Inducement Pla...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Do., 27.03.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that its partner, Takeda Pharmaceutical Company Limited, has received approval by the Japanese Ministry of Health, Labour, and Welfare for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intr...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Di., 11.03.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 17,620 shares of common stock and 9,290 restricted stock units (“RSUs”) to five new employees under Mirum’s 2020 Inducement Plan....
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mi., 26.02.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update. “2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue,” said Chris Peetz, chief executive officer of Mirum. “We continue to expan...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 24.02.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved CTEXLI™ (chenodiol) tablets, a bile acid, for the treatment of adults with cerebrotendinous xanthomatosis (CTX). CTEXLI is the first and only treatment approved for this rare, progressive and debilitating disease. The approval...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mi., 19.02.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2024 financial results on Wednesday, February 26, 2025. Mirum will also host a conference call to discuss the fourth quarter and year-end 2024 financial results and recent corporate progress. Conference call details: Wednesday, February 26,...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Di., 11.02.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on February 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 49,600 shares of common stock and 24,800 restricted stock units (“RSUs”) to 10 new employees under Mirum’s 2020 Inducement Pla...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink
Mo., 13.01.2025       Tokio Marine
US6047491013

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate updates, and full-year 2025 outlook. “2024 marked a significant year for Mirum as we accelerated our commercial business and achieved significant development milestones,” said Ch...
Zur Nachricht
Tokio Marine
Charts & Research Termsheets Terminal
Permalink